Physician profile
Amanda Elder
NPI 1730415100
$2,780.90
in general payments reported to CMS, 2019-2025
28 companies · $928 in 2025
The $928 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $416 · 2023: $594 · 2024: $658 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,109.56 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $474.83 | 2022-2025 | |
| Amgen INC. | $255.65 | 2021-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $213.31 | 2022-2025 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $198.12 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $185.59 | 2021-2023 | |
| Pfizer INC. | $168.86 | 2022-2025 | |
| Novo Nordisk INC | $156.52 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $110.05 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $107.72 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $99.86 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.42 | 2022-2025 | Jardiance |
| Inari Medical, INC. | $93.16 | 2024-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic, INC. | $70.51 | 2024-2025 | Corevalve Evolut R, Intellis Adaptivestim |
| Exact Sciences Corporation | $61.94 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $61.57 | 2021-2024 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $53.63 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $53.14 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $50.20 | 2021-2022 | |
| Dexcom, INC. | $47.71 | 2023-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $46.97 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $35.77 | 2022 | |
| Merck Sharp & Dohme LLC | $34.86 | 2022 | |
| Edwards Lifesciences Corporation | $24.66 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Radius Health, INC. | $21.04 | 2025 | Tymlos |
| Bard Peripheral Vascular, INC. | $18.06 | 2025 | Trek |
| Nabriva Therapeutics, Plc | $14.63 | 2021 | |
| Esperion Therapeutics, INC. | $12.14 | 2022 | |
| Paratek Pharmaceuticals, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Elder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.